Global Cancer Technology
A medical technology company developing a new COVID-19 nanoparticle treatment
COVID-19 Nanoparticle Treatment
Global Cancer Technology is developing a novel technology for killing COVID-19 using activatable light emitting nanoparticles.
Learn more about Global Cancer Technology's COVID-19 nanoparticle treatment by clicking here.
Interested in becoming an investor?
Following the close of an investment round earlier this year at $1 per share, Global Cancer Technology plans to open a new investment round soon at $2 per share. This will be your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment for both COVID-19 and cancer.
Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as UCSD and the University of Washington, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.
Learn more about Global Cancer Technology's remote-controlled cancer drug delivery platform by clicking here.
Beyond its remote-controlled cancer drug delivery platform and COVID-19 nanoparticle treatment, Global Cancer Technology is commercializing its technologies through wholly owned subsidiaries.
Click below to learn more about our subsidiaries.
UCN-01 for sensitizing tumors
Nano quantum dots for tracking medical instruments
‘Boiling histotripsy’ to treat cancer
Nanotechnology treatment for
COVID-19 and cancer